Table 2.
Change in secondary endpoints from baseline to weeks 12 and 24
| Mean change from baseline (week 12) | Mean change from baseline (week 24) | |||||
|---|---|---|---|---|---|---|
| Sitagliptin | α-Glucosidase inhibitor | P-value* | Sitagliptin | α-Glucosidase inhibitor | P-value* | |
| Glycoalbumin (%) | −2.4 (−2.9 to −2.0) | −0.74 (−1.2 to −0.29) | <0.0001 | −2.5 (−3.0 to −1.9) | −1.1 (−1.8 to −0.31) | 0.0026 |
| 1,5-AG (μmol/L) | 21.6 (16.7 to 26.5) | 28.9 (21.9 to 35.9) | 0.089 | 23.2 (16.8 to 29.6) | 32.6 (24.5 to 40.8) | 0.072 |
| Fasting plasma glucose (mmol/L) | −0.60 (−1.1 to −0.092) | 0.26 (−0.16 to 0.68) | 0.010 | −0.54 (−1.0 to −0.066) | −0.15 (−0.60 to 0.29) | 0.24 |
| Fasting insulin (pmol/L) | 6.7 (−5.7 to 18.9) | 5.6 (−9.4 to 20.6) | 0.91 | −0.0088 (−10.6 to 10.6) | −3.4 (−15.0 to 8.3) | 0.67 |
| Fasting C-peptide (nmol/L) | 0.061 (−0.033 to 0.15) | 0.032 (−0.061 to 0.13) | 0.66 | 0.041 (−0.042 to 0.12) | −0.010 (−0.082 to 0.61) | 0.35 |
| Fasting proinsulin-to-insulin ratio | −0.0057 (−0.068 to 0.056) | −0.031 (−0.086 to 0.025) | 0.55 | −0.041 (−0.11 to 0.027) | 0.028 (−0.043 to 0.10) | 0.16 |
| HOMA-β | 10.8 (6.0 to 15.6) | −2.4 (−16.2 to 11.4) | 0.072 | 8.9 (2.7 to 15.2) | −0.60 (−9.2 to 8.0) | 0.078 |
| HOMA-IR | −0.0094 (−1.0 to 1.0) | 0.57 (−0.32 to 1.5) | 0.39 | −0.38 (−1.4 to 0.64) | −0.12 (−0.91 to 0.67) | 0.68 |
| Bodyweight (kg) | 0.25 (−0.12 to 0.62) | −0.39 (−0.68 to −0.093) | 0.0079 | 0.47 (−0.041 to 0.99) | −0.60 (−1.0 to −0.16) | 0.0021 |
| Systolic blood pressure (mmHg) | 1.4 (−2.2 to 5.1) | 1.0 (−1.8 to 3.9) | 0.87 | 1.6 (−1.9 to 5.0) | 0.059 (−3.7 to 3.8) | 0.55 |
| Diastolic blood pressure (mmHg) | −0.47 (−2.6 to 1.7) | 0.67 (−1.9 to 3.2) | 0.49 | −0.38 (−2.2 to 1.4) | 0.80 (−2.8 to 4.4) | 0.55 |
| Heart rate (beats per min) | 1.5 (−1.2 to 4.3) | −1.9 (−4.0 to 0.30) | 0.054 | 0.67 (−2.0 to 3.3) | −2.4 (−5.3 to 0.56) | 0.12 |
| Total cholesterol (mmol/L) | −0.13 (−0.35 to 0.087) | 0.21 (0.065 to 0.36) | 0.010 | −0.11 (−0.34 to 0.11) | 0.18 (0.044 to 0.32) | 0.025 |
| LDL cholesterol (mmol/L) | 0.0066 (−0.15 to 0.16) | 0.21 (0.077 to 0.35) | 0.047 | −0.013 (−0.19 to 0.16) | 0.19 (0.060 to 0.31) | 0.065 |
| HDL cholesterol (mmol/L) | −0.0024 (−0.044 to 0.039) | −0.012 (−0.058 to 0.034) | 0.76 | 0.025 (−0.33 to 0.084) | −0.0025 (−0.047 to 0.042) | 0.45 |
| Triglycerides (mmol/L) | −0.050 (−0.28 to 0.18) | 0.010 (−0.18 to 0.20) | 0.69 | −0.11 (−0.37 to 0.15) | −0.17 (−0.34 to −0.0076) | 0.68 |
| Non-HDL cholesterol (mmol/L) | −0.13 (−0.34 to 0.078) | 0.22 (0.090 to 0.36) | 0.0050 | −0.13 (−0.35 to 0.093) | 0.18 (0.051 to 0.32) | 0.015 |
Changes from baseline to week 12 or week 24 are expressed as least-squares mean change (95% confidence interval).
*
P-value was calculated by comparing the difference from baseline between the sitagliptin and α-glucosidase inhibitor groups. HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA-β, homoeostasis model assessment of β-cell function; HOMA-IR, homoeostasis model assessment of insulin resistance.